Vanguard Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Vanguard Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,153,218	Closed	-$72.1M	–	4142
2026 Q1	$72.1M	Buy	+2,153,218	New	+$84.4M	﹤0.01%	1653

Vanguard Capital Management's SLNO Position: Q2 2026 in Review

Vanguard Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 2,153,218 shares — an estimated $72.1M sold.

Vanguard Capital Management first reported a position in SLNO in Q1 2026 and held it in 1 quarter. The position peaked at $72.1M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Vanguard Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Vanguard Capital Management sold 2,153,218 Soleno Therapeutics shares in Q2 2026, an estimated $72.1M.
Vanguard Capital Management first reported a position in Soleno Therapeutics in Q1 2026 and held it in 1 quarter.
Vanguard Capital Management's Soleno Therapeutics position peaked at $72.1M in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.